EUVIMEDEUVIMED entdecken
Crossref

Safety and efficacy of mirabegron and solifenacin in elderly patient with overactive bladder

Tomasz Wiatr, Piotr Chłosta

Medycyna Faktów · 2021

DOI: 10.24292/01.mf.0121.6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medycyna Faktów, 2021. Verfasst von Tomasz Wiatr und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lower urinary tract symptoms, including urgency, urgency incontinence, pollakiuria and nocturia are common in the elderly people and has significant impact on quality of life. Pharmacological treatment is recommended when conservative management, such as fluid intake normalization or bladder training, does not alleviate symptoms. Antimuscarinics were often used as the I line treatment for OAB, as these drugs block the activity of the muscarinic M2/M3 receptors in the bladder and provide a significant clinical benefit for OAB symptoms in the elderly people, but their side effects are common, often leading to treatment discontinuation. Mirabegron, a β3-adrenoceptor agonist, shows similar efficacy to antimuscarinic drugs without the risk of anticholinergic effects.

Zitieren

APA

Wiatr, T., & Chłosta, P. (2021). Safety and efficacy of mirabegron and solifenacin in elderly patient with overactive bladder. Medycyna Faktów. https://doi.org/10.24292/01.mf.0121.6

Vancouver

Wiatr T, Chłosta P. Safety and efficacy of mirabegron and solifenacin in elderly patient with overactive bladder. Medycyna Faktów. 2021. doi:10.24292/01.mf.0121.6

BibTeX
@article{Wiatr2021,
  author = {Wiatr, Tomasz and Chłosta, Piotr},
  title = {Safety and efficacy of mirabegron and solifenacin in elderly patient with overactive bladder},
  journal = {Medycyna Faktów},
  year = {2021},
  doi = {10.24292/01.mf.0121.6}
}
Kostenlos starten →